Soren Giese – General Manager, Amgen Italy
In a wide-ranging and candid conversation, Amgen Italy General Manager Soren Giese outlines the strategy he put in place to restructure Amgen’s operations in the Italian market, the company’s…
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.
Amgen focuses on areas of high unmet medical need and leverages its biologics manufacturing expertise to strive for solutions that improve health outcomes and dramatically improve people’s lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world’s leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.
Contact
Amgen
Via Tazzoli, 6
20154 – Milano Italia
Tel.: 0039 02 6241121
In a wide-ranging and candid conversation, Amgen Italy General Manager Soren Giese outlines the strategy he put in place to restructure Amgen’s operations in the Italian market, the company’s…
Francesco di Marco, General Manager for Amgen Italy, shares his view on the state of the Italian pharmaceutical sector, the turnaround the company has made in the country, and what…
Sergio Liberatore discusses IMS Health Italy’s evolution after the acquisition of Cegedim’s CRM and strategic data businesses and how IMS is paving the way for pharma companies to become more patient-centric. When we last…
Abramo Brandi, Octapharma Italy’s MD, discusses the challenges of the tender system in Italy and how he has grown the company year-on-year in the midst of a global economic crisis.…
Mario Marazziti, President of the Italian XII Social Affairs Commission, discusses new legislation relating to clinical risk, the effects of the 2014 Pact for Health, and the efficiency of Italian…
Luigi Boggio, President of Assobiomedica, the association representing the medtech industry, and MD of B. Braun Italy, calls on the Italian government to implement a national system that measures the…
GE Healthcare Italy’s Marco Campione discusses patient access to innovation, synergies between pharma and medtech in companion diagnostics, and partnering with the Italian healthcare system. You have been working at…
Having successfully accomplished a four-year turnaround exercise and with a fresh capital injection from a leading Italian PE firm, SIFI executive chairman Fabrizio Chines has ambitious growth objectives for the…
Simona Falciai, General Manager of Shionogi, provides insights into the launch of the Italian affiliate, how the company is catering to a key unmet medical need with Ospemifene, the first…
Outspoken Italian Managing Director of Israeli-based Teva, Hubert Puech d’Alissac, talks about his passion for social responsibility, adapting to the new realities of patient care in the digital age, and…
Giorgio Bruno, CEO of Recipharm Italy, gives an insight into the success factors of the CDMO, discusses the recent acquisition of Mitim, and explains how this acquisition helps Recipharm not…
The president of Chiesi explains how innovation and a strong focus on quality have led to outstanding growth and have established the Italian family-run business as a significant pharma player…
Dr. Osvaldo Ponchiroli, CEO of OP Pharma, discusses the expertise his company can offer to help navigate Italy’s regulatory environment, the outlook for medium-sized generics companies in Italy and OP’s…
Family-owned Laboratori Baldacci is something of a rare breed in an industry dominated by multinational players. The senior research manager discusses the history of the company as well as how…
See our Cookie Privacy Policy Here
